Basement membrane

Frost & Sullivan Co-Published Recombinant Type XVII Collagen Whitepaper with Trautec

Retrieved on: 
Thursday, January 25, 2024
Carbon footprint, Collagen, Research, Basement membrane, Cell adhesion, Shiseido, Tissue, Skin, XVII, Hair loss, Patent, Ageing, B cell, CNY, Growth, Tanning (leather)

Shanghai, China--(Newsfile Corp. - January 25, 2024) -  Frost & Sullivan and Trautec has conducted extensive investigation across the recombinant type xvii collagen and recombinant type XVII collagen industry chain, and co-published Recombinant Type XVII Collagen Whitepaper, which focuses on the recombinant type xvii collagen and recombinant type XVII collagen industry in China as well as new growth opportunities.

Key Points: 
  • Shanghai, China--(Newsfile Corp. - January 25, 2024) -  Frost & Sullivan and Trautec has conducted extensive investigation across the recombinant type xvii collagen and recombinant type XVII collagen industry chain, and co-published Recombinant Type XVII Collagen Whitepaper, which focuses on the recombinant type xvii collagen and recombinant type XVII collagen industry in China as well as new growth opportunities.
  • (To read the Recombinant Type XVII Collagen Whitepaper, go here: https://hub.frost.com/recombinant-type-xvii-collagen/ .)
  • In the process of skin wound repair, type XVII collagen plays a vital role by influencing the migration, proliferation, and differentiation of stem cells.
  • Recombinant Type XVII Collagen Whitepaper highlights the following:
    Recombinant Type XVII Collagen's Biological Functionality(safety, cell adhesion, anti-wrinkle effect, anti-hair loss effect, etc.

JJP Biologics: The European Commission Has Designated JJP-1212 as an Orphan Medicinal Product.

Retrieved on: 
Thursday, October 20, 2022
Oncology, Health, Hospitals, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Union, Blister, Linearity, Royal commission, EMA, Person, Degenerative disease, Patient, JJP, Biotechnology, Severe cognitive impairment, Cancer, Granulocyte, European Medicines Agency, Intention, Basement membrane, Skin, European, Linear IgA bullous dermatosis, Biomarker, European Commission, Pharmaceutical industry

Moreover, currently no approved treatments are available for LABD in the European Union.

Key Points: 
  • Moreover, currently no approved treatments are available for LABD in the European Union.
  • The European Commission has confirmed that, as of the day of submitting the application, LABD could affect approximately 0.3 in 10,000 persons in the European Union.1
    The orphan drug designation of JJP-1212 by the EMA validates the scientific and business choices of JJP Biologics.
  • Having this drug classified into the group of orphan medicinal products provides scientific advice and protocol assistance of the agency.
  • This decision by the European Commission has also a substantial streamlining effect on the clinical development timeline.

Cell Groups Push, Rather than Pull, Themselves Into Place As Organs Form and Cancers Spread

Retrieved on: 
Monday, February 14, 2022
Memorial Sloan Kettering Cancer Center, Biran, NYU, Courant Institute of Mathematical Sciences, Nutrient, New York University Grossman School of Medicine, Tissue, Motion, Basement membrane, NYU Langone Health, Department, Doctor of Philosophy, Erythrocyte deformability, Movement, Animal, Tail, Skeleton, Integrin, Sugar, Cell, Student, National, Mathematical sciences, Advanced Micro Devices, National Institutes of Health, Bacteria, Protein, Adhesive, Cancer, Rubber industry in Malaysia, Software, Nature Cell Biology, Zebrafish, American Heart Association, Foot, Cell biology, National Science Foundation, Microscope, Vaccine, Pharmaceutical industry, New York University

Published online in Nature Cell Biology on February 14, a new study found in a living embryo that the back ends of moving cell groups push the group forward.

Key Points: 
  • Published online in Nature Cell Biology on February 14, a new study found in a living embryo that the back ends of moving cell groups push the group forward.
  • This runs contrary to previous findings, where cell groups grown in dishes of nutrients (cultures) pulled themselves forward with their front edges.
  • The integrin clusters (focal adhesions) observed in the embryo were smaller than those seen in culture studies, and broke down faster.
  • Confirmation of such mechanistic details in living tissue have important implications, say the researchers, as many cancers spread in cell groups, and may use the newfound "rear engine propulsion."

ProgenaCare Global announces effective applications of novel keratin matrix technology, ProgenaMatrix

Retrieved on: 
Wednesday, November 17, 2021
Patient, Skin, VII, Keratin, Industry, JG, Tissue engineering, Basement membrane, Doctor of Philosophy, Solution, Review, Collagen, type IV, alpha 1, View, CMS, Wound healing, Trauma, DPM, Keratinocyte, Multimedia, Silk, Tanning (leather), Medical device

The company's wound care technology, ProgenaMatrix, incorporates human keratin as a major component of the highly effective and affordable wound therapy.

Key Points: 
  • The company's wound care technology, ProgenaMatrix, incorporates human keratin as a major component of the highly effective and affordable wound therapy.
  • The human keratin technology in ProgenaMatrix is hydrated, non-cellular (not tissue-based), non-resorbing and supports the body's own healing process.
  • The bio-inspired design makes ProgenaMatrix the next generation of advanced wound therapy in the CMS skin substitute category.
  • Keratin technology has been in published literature for over a century with applications in wound healing, drug delivery, tissue engineering, trauma and medical devices.1 These studies inspired Progenacare to seek applications of keratin as a wound dressing.